To help officially launch Prostate Cancer Awareness Month, the Prostate Cancer Foundation (PCF) has released a new public service announcement featuring Emmy® Award-winning sports anchor and prostate cancer survivor, Brian Custer. This survivor story aims to raise awareness about the importance of prostate cancer screening among African-American men by delivering a simple message: Man Up and Get Checked.
“As men, we have this ego…we think we’re too macho to go to the doctor and undergo this type of check-up,” said Custer, who hosts Showtime Championship Boxing. “But the truth is: If you don’t get checked, you’re cheating your family out of having a husband or father around. And you’re cheating yourself out of life. I hope when people hear my story, they’re motivated to take action by saying: ‘I’m going to get checked, I’m going to make sure my dad or husband gets checked, too.’”
To view the multimedia release go to:
http://www.multivu.com/players/English/7598151-prostate-cancer-foundation-brian-custer/
The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Inc., and Eisai Inc. today announced the launch of Myths and Truths About Thyroid Cancer, an interactive, educational campaign designed to help dispel the myth that thyroid cancer is a “good cancer.” Because most thyroid cancers can be successfully treated, many are told if you are going to get cancer, thyroid cancer is the one to have, which has led to this misperception. However, whether successfully treated or not, the truth is all cancers can have a significant impact on a person’s life, beginning with the shock and distress of hearing the word “cancer” at diagnosis. In honor of Thyroid Cancer Awareness Month and the tens of thousands who receive a thyroid cancer diagnosis each year, Myths and Truths About Thyroid Cancer illustrates the life-changing realities of this disease.
“As a thyroid cancer survivor, I urge people to stop referring to thyroid cancer as the ‘good cancer,’ as I believe it downplays patients’ experiences,” said Joan Shey, founder of the Light of Life Foundation. “I hear time and time again from patients how difficult their diagnosis and treatment were and that their scars are more than skin deep. My hope is that this campaign can educate about the many types of thyroid cancer and change the thyroid cancer conversation.”
“Being part of a community of survivors is very important for people coping with thyroid cancer,” said Gary Bloom, thyroid cancer survivor and co-founder and executive director of ThyCa: Thyroid Cancer Survivors’ Association. “ThyCa takes this to heart, which is why we are proud to provide support and resources to the thyroid cancer community. We also know more needs to be done to elevate awareness of thyroid cancer and what patients need in terms of support for the rest of our lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7595951-eisai-thyroid-cancer-myths/
For the second year running, Colgate® Optic White® is teaming up with the Country Music Association (CMA) to give fans an insider look at the glamour and excitement around “The 49th Annual CMA Awards” taking place on Wednesday, November 4. To help share that insider story, Colgate Optic White together with two of Country’s brightest stars, Jana Kramer and Cassadee Pope, will share how to look and feel your best whether on or off the red carpet. Starting today, stay in the know on all of the behind the scenes tips and tricks by following @OpticWhite, @CountryMusic, @KramerGirl and @CassadeePope on Twitter.
“When it comes to life’s big moments, the first step to feeling your best is a beautiful smile,” said Kramer. “You can always swap out your shoes or your dress, but your smile is what makes it memorable.”
Colgate Optic White will provide fans with behind the scenes access to Kramer and Pope on their road to the 2015 CMA Awards. Exclusive content and access opportunities include Periscope activations in the weeks leading up to the broadcast and a co-hosted live Twitter chat with Pope on Tuesday, Nov. 3 as well as other surprises. In addition, understanding the importance of social media and fan engagement, @OpticWhite will live-tweet from the red carpet and throughout the CMA Awards, engaging with fans on the brilliant smiles and styles of the night.
To view the multimedia release go to:
http://www.multivu.com/players/English/7566751-colgate-optic-white-cma-awards/
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
As a founding voice in the world of holistic wellness, Canyon Ranch® has the wisdom and expertise of spending nearly 40 years helping its guests achieve well-being. Now, the life-enhancement brand that’s built a devoted global following, is finally going global itself.
Under the guidance of the brand’s new Chief Executive Officer, Susan E. Docherty, the Company announced today the development of its first-ever international destination, Canyon Ranch Wellness Resort at Kaplankaya, on a spectacular peninsula of the sun-kissed Aegean coast. The initial phase of the Canyon Ranch development, which will open in July 2016, will include a strikingly modern resort and luxury real estate offerings. The property will integrate the signature wellness and lifestyle programming that has earned Canyon Ranch a famously loyal clientele worldwide.
To view the multimedia release go to:
http://www.multivu.com/players/English/7634751-canyon-ranch-resort-kaplankaya-turkey/
New Orleans is one of the country’s most culturally, architecturally, and musically interesting cities. It will serve as the picturesque backdrop for Team Challenge, the Crohn’s & Colitis Foundation of America’s (CCFA) endurance training and fundraising program, to take over the city on February 28, 2016 for the Rock ‘n’ Roll New Orleans Marathon, Half Marathon & 10k.
For the first time ever, Team Challenge is recruiting for participants to run through the Big Easy while raising critical funds and awareness of Crohn’s disease and ulcerative colitis. Collectively known as inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis are painful, medically incurable diseases that attack the digestive system. There are more than 1.6 million Americans living with these chronic, debilitating diseases.
“Team Challenge provides people with an opportunity to raise critical research dollars while training to do something that, for many people, they never imagined they’d be able to do,” said Craig Comins, vice president of Team Challenge. “It is inspiring to see a group of people come together, some who have these diseases and some who do not, united in the mission of finding a cure for Crohn’s disease and ulcerative colitis.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7512652-ccfa-team-challenge-recruit-nola/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The largest candy-consumption night of the year is right around the corner. More than 80 percent of parents say their kids will participate in a Halloween celebration (2), and when asked about concerns related to Halloween, more than two-thirds of parents say they are worried about their children’s teeth, according to a recent Ad Council survey (1). However, three out of four parents report that their kids sometimes or frequently forget to brush their teeth on a daily basis. With cavities being a top concern, the Kids’ Healthy Mouths campaign is celebrating National Brush Day® on Sunday, November 1, the day after Halloween, to emphasize the importance of brushing for two minutes, twice a day, every day.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7676151-kids-healthy-mouths-ad-council-brush-day/
(1), (2) The Ad Council’s survey was conducted by LightSpeed Research in September 2014. The nationally representative online survey included 600 parents with children 0-12.
